Maintenance therapy in multiple myeloma: Two is not always better than one

In multiple myeloma (MM) long‐term therapy aims to control disease and delay progression for as long as possible. In this issue Jenner et al. failed to demonstrate a benefit of maintenance with lenalidomide plus vorinostat compared with lenalidomide in both transplant eligible (TE) and ineligible (N...

Full description

Saved in:
Bibliographic Details
Published in:British journal of haematology 2023-04, Vol.201 (2), p.181-182
Main Authors: Offidani, Massimo, Morè, Sonia, Corvatta, Laura
Format: Article
Language:English
Subjects:
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Dexamethasone - therapeutic use
Hematology
Humans
Lenalidomide - therapeutic use
maintenance
Multiple myeloma
Multiple Myeloma - therapy
Treatment Outcome
Vorinostat
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:In multiple myeloma (MM) long‐term therapy aims to control disease and delay progression for as long as possible. In this issue Jenner et al. failed to demonstrate a benefit of maintenance with lenalidomide plus vorinostat compared with lenalidomide in both transplant eligible (TE) and ineligible (NTE) patients enrolled in the Myeloma XI trial. Commentary on: Jenner et al. The addition of vorinostat to lenalidomide maintenance for patients with newly diagnosed multiple myeloma of all ages: results from ‘Myeloma XI’, a multicentre, open‐label, randomised, phase III trial. Br J Haematol. 2023;201:276‐288.
ISSN:0007-1048
1365-2141
DOI:10.1111/bjh.18614